Bonnie H. Anderson net worth and biography

Bonnie Anderson Biography and Net Worth

Insider of Veracyte

Bonnie H. Anderson has served as our co-founder, Chief Executive Officer and as a member of our board of directors since February 2008 and as the Chairman of our board of directors since December 2016. From August 2013 to February 2017, she also served as our President. Prior to joining us, Ms. Anderson was an independent strategic consultant from April 2006 to January 2008, including as a strategic consultant for us from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Bruker Corporation and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson previously served as a member of the board of directors of Castle Biosciences, Inc. from June 2015 to August 2020. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania.

What is Bonnie H. Anderson's net worth?: The estimated net worth of Bonnie H. Anderson is at least $1.67 million as of April 14th, 2023. Ms. Anderson owns 42,681 shares of Veracyte stock worth more than $1,673,095 as of November 21st. This net worth approximation does not reflect any other investments that Ms. Anderson may own. Learn More about Bonnie H. Anderson's net worth.
How do I contact Bonnie H. Anderson?: The corporate mailing address for Ms. Anderson and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Bonnie H. Anderson's contact information.
Has Bonnie H. Anderson been buying or selling shares of Veracyte?: Bonnie H. Anderson has not been actively trading shares of Veracyte during the last quarter. Most recently, Bonnie H. Anderson sold 34,000 shares of the business's stock in a transaction on Friday, April 14th. The shares were sold at an average price of $22.04, for a transaction totalling $749,360.00. Following the completion of the sale, the director now directly owns 42,681 shares of the company's stock, valued at $940,689.24. Learn More on Bonnie H. Anderson's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 63,827 shares worth more than $1,779,423.17. The most recent insider tranaction occured on September, 19th when Director Evan/ Fa Jones sold 5,173 shares worth more than $182,244.79. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 9/19/2024.

Bonnie H. Anderson Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/14/2023	Sell	34,000	$22.04	$749,360.00	42,681
3/15/2023	Sell	34,000	$22.76	$773,840.00	53,967
1/17/2023	Sell	34,000	$26.35	$895,900.00	62,961
1/11/2023	Sell	63,247	$25.13	$1,589,397.11	62,961
12/1/2022	Sell	80,000	$28.26	$2,260,800.00	65,003
9/17/2021	Sell	2,600	$50.18	$130,468.00
9/10/2021	Sell	1,900	$50.03	$95,057.00
1/12/2021	Sell	20,354	$50.20	$1,021,770.80	268,938
10/8/2020	Sell	50,000	$38.00	$1,900,000.00	270,231
9/10/2020	Sell	20,000	$30.89	$617,800.00	240,231
7/30/2020	Sell	11,365	$32.24	$366,407.60	283,572
7/23/2020	Sell	3,280	$32.04	$105,091.20	275,487
7/21/2020	Sell	3,447	$32.09	$110,614.23	274,060
6/10/2020	Sell	20,000	$26.56	$531,200.00	292,207
5/11/2020	Sell	20,000	$26.67	$533,400.00	274,183
3/10/2020	Sell	20,000	$25.18	$503,600.00	276,313
1/10/2020	Sell	20,000	$28.86	$577,200.00	137,738
11/15/2019	Sell	20,000	$25.06	$501,200.00	123,726
10/10/2019	Sell	8,000	$24.50	$196,000.00	109,467
9/10/2019	Sell	8,000	$24.51	$196,080.00	111,028
8/12/2019	Sell	8,000	$25.28	$202,240.00	121,414
7/10/2019	Sell	8,000	$28.79	$230,320.00	127,955
6/10/2019	Sell	8,000	$26.33	$210,640.00	127,955
5/10/2019	Sell	8,000	$22.99	$183,920.00	103,292
4/10/2019	Sell	8,000	$25.39	$203,120.00	103,292
3/11/2019	Sell	8,000	$19.97	$159,760.00	110,592
2/26/2019	Sell	20,000	$20.94	$418,800.00
2/11/2019	Sell	8,000	$18.17	$145,360.00	84,541
1/10/2019	Sell	25,500	$15.29	$389,895.00	94,041
12/10/2018	Sell	8,000	$12.13	$97,040.00	59,236
11/12/2018	Sell	23,305	$13.42	$312,753.10	75,846
8/27/2018	Sell	6,000	$12.00	$72,000.00	58,541
8/2/2018	Sell	14,950	$11.50	$171,925.00	67,491
7/23/2018	Sell	6,000	$10.20	$61,200.00	58,541
6/25/2018	Sell	6,000	$9.26	$55,560.00	57,627
6/12/2018	Sell	12,000	$8.00	$96,000.00
10/20/2017	Sell	16,000	$9.41	$150,560.00	16,000
10/18/2017	Sell	6,000	$9.09	$54,540.00	16,000
9/25/2017	Sell	6,000	$8.44	$50,640.00	16,000
3/21/2017	Sell	5,000	$9.09	$45,450.00	15,000
6/3/2016	Buy	5,000	$5.40	$27,000.00	7,500
6/1/2016	Buy	5,000	$5.46	$27,300.00	2,500
5/31/2016	Buy	2,500	$5.46	$13,650.00	2,500
6/27/2014	Sell	1,000	$17.95	$17,950.00
6/23/2014	Sell	4,000	$16.45	$65,800.00

Bonnie H. Anderson Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Today's Range

Now: $39.20

$38.61

$39.80

50 Day Range

MA: $34.40

$30.32

$39.53

2 Week Range

Now: $39.20

$18.61

$41.43

Volume

631,390 shs

Average Volume

871,517 shs

Market Capitalization

$3.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.